The market correctly sees biology's potential but often misunderstands its timeline. Even with AI, biology is fundamentally harder and slower than software. Daniel Fero warns this mismatch in "tempo" expectations leads to over-funding hype cycles while under-funding foundational companies that are simply moving at the pace required for rigorous biological R&D.

When raising a first fund, you sell a future vision. To make this tangible, OMX Ventures leveraged founders they had previously supported. These founders served not only as powerful references but also became Limited Partners (LPs) in the new fund, providing the ultimate validation of the VC's value-add and building a loyal capital base.

A common mistake for emerging managers is pitching LPs solely on the potential for huge returns. Institutional LPs are often more concerned with how a fund's specific strategy, size, and focus align with their overall portfolio construction. Demonstrating a clear, disciplined strategy is more compelling than promising an 8x return.

The biggest venture outcomes often take 8-10 years or more to mature. Instead of optimizing for quick IRR, early-stage VCs should embrace long holding periods. This "duration" is a feature that allows for massive value creation and aligns with building truly transformative companies, prioritizing multiples over short-term gains.

Zipline's journey highlights a mismatch between standard VC fund timelines (10-12 years) and the longer development cycles of "real-world tech" like robotics. Founders in these spaces must be prepared for a 15-20 year journey and communicate this reality to investors from the start.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Drug development can take a decade, a timeframe that misaligns with typical investor horizons and employee careers. Success requires navigating fluctuating capital market cycles and implementing strategies to retain key scientific talent for the long haul.

Despite perceptions of quick wealth, venture capital is a long-term game. Investors can face periods of 10 years or more without receiving any cash distributions (carry) from their funds. This illiquidity and delayed gratification stand in stark contrast to the more immediate payouts seen in public markets or big tech compensation.

The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.